First experience with brentuximab vedotin in posttransplant lymphoproliferative disorder after liver transplantation: complete remission followed by lethal sepsis.
Gastroenterology and Hepatology, Department of Medicine II, Medical University of Innsbruck, Innsbruck, Austria.
Benedikt
B
Schaefer
Michael
M
Steurer
Bernhard
B
Glodny
Daniel
D
Neureiter
Patrizia
P
Moser
Livia
L
Dorn
Wolfgang
W
Vogel
Heinz
H
Zoller
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001706:Biopsy; D000079963:Brentuximab Vedotin; D017809:Fatal Outcome; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016031:Liver Transplantation / Q000009:adverse effects*; D017728:Lymphoma, Large-Cell, Anaplastic / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D012307:Risk Factors; D018805:Sepsis / Q000175:diagnosis / Q000382:microbiology* / Q000628:therapy; D013997:Time Factors; D014057:Tomography, X-Ray Computed
D000970:Antineoplastic Agents; D018796:Immunoconjugates; D007166:Immunosuppressive Agents; D000079963:Brentuximab Vedotin